DJIA 16,805.41 127.51 0.76%
NASDAQ 4,483.72 30.92 0.69%
S&P 500 1,964.58 13.76 0.71%
market minute promo

4.17 0.07 (1.71%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ARNA $4.17 1.71%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.12
Previous Close $4.10
Daily Range $4.10 - $4.18
52-Week Range $3.26 - $7.97
Market Cap $916.7M
P/E Ratio -15.77
Dividend (Yield) $0.00 (0.0%)
Volume 1,742,869
Average Daily Volume 4,409,495
Current FY EPS -$0.35

Sector

Healthcare

Industry

Drugs

Arena Pharmaceuticals, Inc. (ARNA) Description

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Website: http://www.arenapharm.com/

News & Commentary Rss Feed

Could Arena Pharmaceuticals Inc. Be Running Out of Money?

Biotech stocks running out of money is a common concern for investors of clinical-stage and early commercial stage stocks. Let's take a closer look at Arena Pharmaceuticals' current cash situation and determine whether or not current investors should be worried.

Assessing Arena Pharmaceutical Belviq Sales And The Impact Of TV Ads

Arena Investors Need To Watch Contrave Launch Closely

Bank Of America Q3 Small & Mid-Cap Biotech Preview

Orexigen Launches Contrave - Watch For Traction

Belviq Sales Dip: What To Watch For Ahead

Biotech Stock Mailbag: Small-Cap Rebound, Avanir, Ohr, CytoSorbents

What To Watch For As Orexigen's Launch Approaches

Pfizer Setback Could Help Arena

Belviq Sales Rise Almost 5% Week Over Week

See More ARNA News...

ARNA's Top Competitors

ARNA $4.17 (1.71%)
Current stock: ARNA
AMGN $147.26 (0.01%)
Current stock: AMGN
GILD $110.71 (3.29%)
Current stock: GILD
BIIB $321.67 (1.77%)
Current stock: BIIB